Introduction
Besides human follicular B-cell lymphomas, in which the bcl-2 gene was originally found (Tsujimoto et al., 1984; Bakhshi et al., 1985; Cleary et al., 1986) , bcl-2 overexpression has been observed in a variety of human tumors, thus providing the ®rst indication of BCL-2 involvement in human cancer (Silvestrini et al., 1994; Korsmeyer et al., 1990) . Many other studies in experimental systems (McDonnell et al., 1996) such as bcl-2 transgenic (Strasser et al., 1990; Adams and Cory, 1991) or knock-out mice (Nakayama et al., 1993; Korsmeyer, 1998; Veis et al., 1993) have directly related BCL-2 antiapoptotic activity to neoplastic transformation and/or progression. BCL-2 protein has been shown to lower cell sensitivity to chemotherapy and radiotherapy (Reed et al., 1996; Kroemer, 1997) . On the contrary, reduced bcl-2 expression has been associated to degenerative disorders including Parkinson's disease or Alzheimer's disease (Saille et al., 1999) .
Many attempts have been made to develop biological or pharmacological means of modulating bcl-2 expression (Konig et al., 1997; Itano et al., 1996; Siegel et al., 1998) . Antisense compounds have shown biological activity in switching o bcl-2 expression in cell (Capaccioli et al., 1996; Morelli et al., 1996 Morelli et al., , 1997 , and are currently under clinical evaluation for antilymphoma activity (Webb et al., 1997) and for chemosensitization (Jansen et al., 2000) . Both microtubule-stabilizing agents such as taxol and microtubuledamaging compounds such as nocodazole have been shown to mediate phosphorylation of BCL-2 protein at serine residues in the loop region (Srivastava et al., 1999; Blagosklonny et al., 1996) ; phosphorylation inactivates the antiapoptotic eect. Microtubule damage induced by pharmacological means may trigger apoptosis in cancer cells through a mechanism involving BCL-2 phosphorylation (Haldar et al., 1996) . Moreover, arrest of cells in G 2 -M phase consequent on damage to the mitotic apparatus may be responsible for triggering a physiological mechanism of cell demise. The biochemical pathways that link microtubule damage with the BCL-2 phosphorylationinactivation leading the cells to activate apoptotic programs, are not yet well known (Yamamoto et al., 1999; Li et al., 1998) .
Previously, in lymphoid cells, we observed that the cell cycle arrest in G 1 phase by rapamycin was regulated by the amount of the BCL-2 protein expressed at the steady state. These observations prompted to study whether rapamycin might regulate the BCL-2 pathway and apoptosis in cells treated with taxol, a pro-apoptotic compound that damages microtubules and down-regulates BCL-2.
In mammalian cells, the immunophilin-binding immunosuppressant rapamycin was shown to inhibit mammalian target of rapamycin (mTOR/RAFT-1/ FRAP), a serine/threonine kinase whose function is not entirely understood (Sehgal, 1998) . In yeast, rapamycin-mediated inhibition of TOR1 and TOR2, two kinases homologous to human mTOR, induces a starvation-like response and can hinder the cell cycle-dependent organization of the cytoskeleton (Bickle et al., 1998) . In human, mTOR is mainly implicated in the signaling of cell growth and proliferation from growth factors and amino acids abundance (Hara et al., 1998; Nave et al., 1999) . More recently, mTOR has been shown to control an unusually abundant and diverse set of readouts, eliciting to the spatial and temporal control of balanced cell growth (Schmelzle and Hall, 2000; Choi et al., 2000) .
In this study human follicular B-cell lymphoma lines endowed with high levels of BCL-2 at steady state were exposed to rapamycin. We found that rapamycin was able to increase cellular levels of BCL-2 protein in addition to p27 kip1 protein.
Prior treatment of cells with rapamycin inhibited taxol-induced apoptosis and DNA endoreduplication (Stewart et al., 1999) , while having no eect on microtubule stabilization and on arrest in the G 2 -M phase. Prediction was made that the mTOR kinase was activated by antimicrotubules agents and might be included in the kinase cascade whereby the apoptosis triggered by microtubule damage is brought about.
Result
Rapamycin induces the selective accumulation of BCL-2 and p27 kip1 proteins
In a program to study the molecular mechanisms regulating bcl-2 expression, we found that rapamycin inhibited the cell growth of follicular lymphoma cell lines very eciently. In three human follicular t(14;
18)-positive cell lines, cells were arrested in the G 1 phase of the cell cycle at doses not eective in t(14; 18)-negative cell lines (Table 1 ). The activity of rapamycin was dose-dependent and at 1 ng/mL the percentage of G 1 fraction was 36% higher than in the untreated control. Moreover, rapamycin did not increase the hypodiploid cell fraction and in preliminary studies apoptosis induced by pharmacological means was reduced. These ®ndings and those of others (Kitamura et al., 1997; Migita et al., 1997) prompted us to measure the cellular levels of BCL-2 protein and of the relevant mRNA. These last were not modi®ed upon exposure to rapamycin (not shown), whilst those of the BCL-2 protein increased up to threefold upon the same treatment. As expected, the cellular level of the p27 kip1 protein underwent the same fate (Figure 1a ). In the same assays, the concentrations of the apoptosisrelated protein BCL-X L or BAX and of the cell-cycle regulators p21, CDK 2 and Cyclin E were not augmented. The increases of BCL-2 and p27 kip1 proteins were dependent on the rapamycin concentration. The levels reached a peak after 24 h and were still high after 48 h (Figure 1b) .
These ®ndings indicated that a post-transcriptional mechanism could underlie the rapamycin-mediated BCL-2 increase as it does with p27 kip1 (Vlach et al., 1997) .
Rapamycin inhibits taxol-induced BCL-2 phosphorylation, DNA endoreduplication and apoptosis
The rapamycin-mediated inactivation of the kinase cascade starting from mTOR might account for the rapamycin-mediated inhibition of BCL-2 phosphorylation. By contrast, taxol treatment can phosphorylate BCL-2 causing functional inactivation. Cells were incubated 24 h with rapamycin and then treated with taxol for further 24 h. As shown in Figure 2 , rapamycin prevented taxol-induced BCL-2 phosphorylation in a dose-dependent fashion. In these studies taxol has been used within the clinical relevant doses Rapamycin was given as a single dose at the indicated concentrations on day 0. On day 3, cultures were arrested and cells were counted under the microscope and analysed by the MTT assay. Assays were performed in triplicate and data are representative of 4 ± 6 experiments. Cell cycle was studied in cells incubated for 24 h in the presence of 3, 1 or 0.3 ng/mL of rapamycin, respectively. The percentage distribution over the cell cycle was measured by¯ow cytometry. **P40.005, *P40.05
(5 ± 200 nM) (Blagosklonny and Fojo, 1999) or at higher doses to understand the magnitude of inhibition of phosphorylation by a low dose of rapamycin. The biochemical mechanisms underlying taxol activity were studied in some detail in the rapamycinpretreated cells, with more emphasis in the BCL-2 overexpressing lymphoma B-cell lines. At the end of the pharmacological treatments, genomic DNA was stained with propidium iodide and analysed by¯ow cytometry. Figure 3 shows that combined treatment with rapamycin and taxol caused the arrest in G 2 -M phase of a higher number of cells (70% of total cells) than taxol alone (50% of cycling cells). Taxol was probably more eective than rapamycin in arresting cell cycle causing G1 arrested cells by rapamycin to accumulate into the more de®nitely G 2 -M phase arrest.
A second observation was that rapamycin totally inhibited the ability of taxol to induce mitotic slippage shown as 44N in Figures 3 and 4 . Thus, taxol did not relieve the inhibition of DNA synthesis by rapamycin, which entirely blocked endoreduplication. Cytometry analysis also showed that rapamycin protected cells from taxol-induced apoptosis.
The DNA distribution in rapamycin pre-treated cells exposed to increasing doses of taxol was extensively studied in lymphoma lines including three t(14; 18) lymphoma lines. Rapamycin was con®rmed to inhibit with high eciency the biological eects of taxol as studied by¯ow cytometry. In particular, apoptosis was reduced signi®cantly and hyperploidy completely, in spite of the heavy alteration produced by a high dose of taxol as shown in Figure 4 .
Taxol-mediated microtubule stabilization is not impaired in cells pretreated with rapamycin
Since the main biochemical eect of taxol is to stabilize the microtubule apparatus, which activates the apoptotic program, we studied the eect of taxol on microtubule stabilization in rapamycin-pretreated cells. Figure 5a was obtained by staining microtubules with¯uorescent a-tubulin antibodies and shows that the stabilization of microtubules by 2 h exposure of cells to taxol was not impaired by prior treatment with rapamycin. Figure 5b shows that the accumulation of cells treated with taxol in the prometaphase is not signi®cantly inhibited by a pretreatment with rapamycin.
Taxol or nocodazole activate the serine/threonine mTOR kinase
Because taxol phosphorylates BCL-2 protein and rapamycin inhibits this phosphorylation by acting on mTOR, we investigated whether taxol might induce the activation of mTOR. Taxol indeed induced the Figure 6 (lower panel). Extracts from K422 cells, treated 24 h with dierent doses of taxol, were immunoprecipitated with both mTab1 and mTab2 rabbit antibodies and resuspended in the kinase buer containing recombinant PHAS-I or recombinant BCL-2. mTOR immunoprecipitates from cells treated with 300 or 30 nM of taxol were able to phosphorylate PHAS-I, while 3 nM was almost ineective. However, a direct activity of mTOR on BCL-2 might be excluded since recombinant BCL-2 in the kinase buer was not phosphorylated by activated mTOR (not shown). Figures 7 and 8 show that mTOR activity triggered by taxol or nocodazole, respectively, was signi®cantly reduced in the immunoprecipitated samples from cells pre-treated with rapamycin. The Western blot determination of mTOR in the immunoprecipitates ruled out the possibility that reduced activity might be dependent on the failure of antibody to immunoprecipitate the rapamycin-FKBP12-mTOR complex.
Therefore, mTOR, the molecular target for the biological eects of rapamycin, recently strengthened by studies in cells carrying mTOR resistant to rapamycin, strongly associate it to the kinase cascade that phosphorylates BCL-2 in mitotic arrested cells .
Discussion
Very important pathways of cell life such as protein synthesis, cell proliferation and apoptosis are often controlled in a coordinated fashion (Lundberg and Weinberg, 1999; Guo and Bruce, 1999 ) by growth factors. Rapamycin, by inhibiting protein synthesis (Crossin and Carney, 1981; Terada et al., 1995) and arresting the cell-cycle in G 1 (Hashemolhosseini et al., 1998; Metcalfe et al., 1997) is able to induce a`growthfactor withdrawal' condition . Whether starvation conditions induced by rapamycin can play some role in the regulation of the apoptotic programs activated by pharmacological means is not yet well known (Abraham, 1998) .
Rapamycin activates an anti-apoptotic program
The biochemical events triggered by rapamycin were studied in three human follicular B-cell lymphoma lines that contain a high concentration of BCL-2 protein (Aiello et al., 1992; Steube et al., 1995) and are most sensitive to rapamycin. The lowest doses of rapamycin inhibited growth and arrested the cell lines in the G 1 phase. In these studies it was also noticed that cell cultures were protected from spontaneous apoptosis and from apoptosis induced by treatments with taxol. Inactivation of the apoptotic program prompted our studies on the expression of the bcl-2 gene in cells exposed to rapamycin. We observed that the cellular concentration of the bcl-2 mRNA was unchanged, whereas that of BCL-2 protein was signi®cantly increased in a dose-dependent fashion and correlated with the increased level of p27 kip1 protein (Ko and Polyak, 1995; Alessandrini et al., 1997; Cordon-Cardo et al., 1998) . The increased level of the proteins by rapamycin was speci®c for BCL-2 and p27 kip1 , since the cell concentrations of neither the apoptosis-related proteins BCL-X L and BAX nor the cell-cycle regulators p21, CDK-2 and cyclin-E were changed. This observation suggested that BCL-2 and Figure 3 DNA distribution in rapamycin pre-treated cells exposed to taxol treatments. DOHH 2 cells, treated with rapamycin, 10 ng/mL at time 0, on day 1 were untreated or treated with taxol at 300, 30 or 3 nM for a further 24 h. Cells, stained with propidium iodide, were analysed by¯ow cytometry. Upper rows, no rapamycin (7); lower rows, rapamycin 10 ng/mL (R). In the top-right of the histograms are indicated the percentage of hypodiploid cells (Hypo) or hyperdiploid cells (44N), respectively.
Histograms are representative of 4 ± 5 experiments
Oncogene mTOR regulates apoptosis and cell cycle A Calastretti et al p27 kip1 could be modulated by common pathways or a coordinated mechanism. Such biochemical modi®ca-tions are associated with the activation of an antiapoptotic program and with the arrest of cells in the G 1 phase.
Damaged microtubules activate the mTOR kinase
Taxol can induce BCL-2 phosphorylation at position serine (Srivastava et al., 1999; Haldar et al., 1997) causing the inactivation of BCL-2 (Chadebech et al., 1999) and consequent loss of anti-apoptotic function. BCL-2 phosphorylation and the pro-apoptotic program triggered by taxol in the lymphoma cells were greatly inhibited by prior treatment with rapamycin in a dose-response manner. Moreover, prior treatment with rapamycin completely inhibited the taxol-induced hyperdiploidy but did not prevent taxol-induced microtubule damage.
The inhibition of BCL-2 phosphorylation despite microtubule alteration, prompted us to study the biochemical signaling activated by microtubules. Our attention has been focused on the threonine/serine mTOR kinase. The immunoprecipitation studies provided evidence that treatment with taxol or nocodazole activated mTOR which indicated an important role in the kinase cascade regulating BCL-2 phosphorylation and loss of function.
In the ®rst part of the work we show that rapamycin is able to increase the cellular level of the BCL-2 protein and protect lymphoma cells from apoptosis. The increase of BCL-2 protein is achieved by inhibition of BCL-2 phosphorylation and might be more evident in cells containing a large amount of Figure 4 DNA distribution in rapamycin pre-treated t(14; 18) cells exposed to taxol at high dose. SU-DHL-4, DOHH 2 and K422 cell lines, were untreated (7), treated with rapamycin, 48 h at 10 ng/mL (R), treated with taxol, 24 h at 300 nM (T), or pre-treated with rapamycin, 24 h at 10 ng/mL, and with taxol for a further 24 h at 300 nM (R+T). Cells were processed as in Figure 3 and histograms are representative of three experiments mTOR regulates apoptosis and cell cycle A Calastretti et al BCL-2 in the steady state. We show here that agents that damage microtubules can induce BCL-2 phosphorylation-inactivation through a pathway that involves the mTOR kinase. This pathway might be a physiological mechanism for the elimination of cancer cells with damaged mitotic apparatus (Haldar et al., 1997) . In contrast, impaired mTOR activity, such as that mediated by rapamycin, might hinder the elimination of damaged cells inducing resistance to anticancer therapy or protecting tissues from degeneration. In this scenario, the role of p27 kip1 remains to be elucidated. Taxol has never been directly demonstrated to inactivate p27 kip1 by phosphorylation. The concept of p27 kip1 inactivation might not be in contrast with the observation of hyperdiploidy in cells hampered to divide because of damage of mitotic apparatus. However, the possibility that taxol does not enter in the regulation of p27 kip1 already inactivated by signals from the growth factors cannot be ruled out.
In conclusion, damaged microtubules can induce an apoptotic program by activating a biochemical cascade that includes serine/threonine kinases and mTOR. The ®ndings discussed here might indicate a key role for the mTOR kinase in relevant metabolic steps of the G 2 -M phase in addition to the role of central controller of cell growth. A coordinate regulation of cell cycle and apoptosis by means of mTOR might be envisaged.
Material and methods

Cell lines and drugs
The human follicular B-cell lymphoma lines DOHH 2 (KluinNelemans et al., 1991), SU-DHL-4 (Cleary et al., 1986) and K422 (Dyer et al., 1990) , carrying the t(14; 18) chromosomal translocation, all mycoplasma-free, were grown in RPMI Figure 6 mTOR protein kinase activity from cells treated with taxol. K422 cells, treated with taxol, 24 h at 300, 30 or 3 nM, were lysed and extracts, quantitated by Western blottings (lower panel), were immunoprecipitated either with mTAb1 or with mTAb2 rabbit antibodies, respectively. The substrate for the kinase reactions was the human recombinant PHAS-I. The products were separated by SDS ± PAGE and detected by autoradiography. Data are representative of three assays 1640 medium (Mascia Brunelli, Milan, Italy) containing 10% heat-inactivated FCS (HyClone Laboratories, UT, USA), 2 mM glutamine, 50 IU/mL penicillin and 50 mg/ml streptomycin (Sigma-Aldrich, Milan, Italy) at 378C in a 5% CO 2 atmosphere. The nucleotide sequence of the bcl-2/IgH joining region of the t(14; 18)-positive cells were frequently checked. Rapamycin, kindly supplied by Dr Sehgal (WyethAyerst Research, NJ USA), was dissolved in absolute ethanol to generate a 2 mM solution and small aliquots of the stock solution were stored at 7808C. Taxol and Nocodazole (Sigma-Aldrich) were dissolved in DMSO to generate a 1 mM solution or 10 mM solution, respectively and small aliquots of the stock solutions were stored at 7208C.
Growth rate assay
Cultures, 25 ± 100610 3 cells/mL in 24-well plates (Greiner), split twice weekly to avoid crowding, were washed, resuspended in RPMI 1640 medium (Mascia Brunelli) containing 10% FCS and the same glutamine and antibiotic concentrations as above and exposed to rapamycin as indicated. Growth rate and viability of the cells were determined by the Trypan blue exclusion assay and by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-based colorimetric assay (Mosmann, 1983) .
Western blot analysis of the proteins
Samples of 4610
6 cells, treated with rapamycin as indicated, were collected by low-speed centrifugation and washed twice in ice-cold PBS plus 1 mM sodium orthovanadate. The cell pellet was resuspended in 60 mL of lysis buer (ice-cold RIPA buer with freshly added protease inhibitors), vortexed for 3 s and incubated on ice for 30 min. The lysates were centrifuged at high speed for 20 min at 48C. Five mL of the supernatant was removed for protein determination, transferred to a microfuge tube, mixed with reducing buer and heated to 998C for 2 min. Equal amounts of proteins, unless speci®ed, were analysed by 12% SDS ± PAGE, blotted onto PVDF membranes (Immobilon P, Millipore, Bedford, MA, USA) in a Bio-Rad Trans-blot apparatus at 100 V for 90 min. Blots were processed by an enhanced chemiluminescence (ECL Plus) detection kit as instructed by the supplier (Amersham Pharmacia Biotech, UK). The blots were probed with a mouse anti-BCL-2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), followed by a horseradish peroxidase, conjugated secondary antibody. The same blots were then Figure 7 mTOR protein kinase activity from cells pre-treated with rapamycin and treated with taxol. K422 cells, treated with rapamycin, 10 ng/mL at time 0, on day 1 were untreated or exposed to taxol for a further 24 h at the doses indicated. Cell extracts were obtained and processed as described in Figure 6 . Data are representative of three assays Figure 8 mTOR protein kinase activity from cells pre-treated with rapamycin and treated with nocodazole. DOHH2 cells, treated with rapamycin, 10 ng/mL at time 0, on day 1 were untreated or exposed to 1, 0.3, 0.1 mM nocodazole for a further 24 h at the doses indicated. Cell extracts were obtained and processed as described in Figure 6 . Data are representative of three assays mTOR regulates apoptosis and cell cycle A Calastretti et al probed for p27 kip1 and BAX (DAKO, Milan, Italy), p21 (NeoMarkers, Freemont, CA, USA), BCL-X L (Pharmingen, San Diego, CA, USA), CDK2 and Cyclin E (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and for b-actin (Sigma-Aldrich) using appropriate antibodies.
Western blot analysis for the phosphorylated form of BCL-2 protein Samples of 8610 6 cells, treated with rapamycin and taxol as indicated, were collected and resuspended in 320 mL of Laemmli buer (Laemmli, 1970) , boiled for 2 min, protease inhibitors were added and the mixture was sonicated for 20 s. Supernatants containing protein extracts were collected and a 1 : 10 volume of BMG (glycerol:b-mercaptoethanol: bromophenol-blue, 1%/2 : 5 : 5) was added; they were then boiled for 3 min and stored at 7208C. Protein concentration was determined using the Micro BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). Aliquots of 130 mg were sizeseparated by SDS ± PAGE (12%, 1.5 mm thick gel 70.8% Bis-acrylamide/30% acrylamide) at 80 V overnight and blotted onto a PVDF membranes (Immobilon P) in a BIO-RAD Trans-Blot semi-dry apparatus at 15 V for 60 min. Immunodetection was carried out using an anti-BCL-2 (DAKO, Milan, Italy) monoclonal antibody (1 : 100), and blots were successively developed with peroxidase anti-mouse antibody (1 : 2000), using the enhanced chemiluminescence kit (Pratesi et al., 2000) .
Analysis of cellular DNA content by flow cytometry
Cells treated as indicated were collected and washed in PBS for 10 min at 1500 r.p.m., then permeabilized with 200 mL of PBS containing 0.1% Saponin and 0.5 mg/mL RNAse (type IIIA, Sigma-Aldrich) for 30 ± 40 min at 378C. Eight hundred mL of DNA-staining solution, 0.1% saponin and propidium iodide (25 mg/mL in PBS), were added for 30 min at 48C (Nicoletti et al., 1991) . The cellular DNA content was analysed by¯ow cytometry with a FACscan (Becton Dickinson, CA, USA). Histograms of cell frequency vs propidium iodide¯uorescence intensity, which is proportional to DNA content, were analysed using the Lysis II software system (Becton Dickinson).
Microtubule staining and Mitotic Index
The distribution of a-tubulin was analysed by the indirect immuno¯uorescence technique (Schi and Horwitz, 1980) . The cells, treated as indicated, were ®xed and permeabilized for 5 min with methanol at 7208C, washed with PBS 1X and incubated with monoclonal anti-a-tubulin conjugated with FITC (1 : 75 in PBS+0.05% Triton X) (Sigma-Aldrich), in a humid atmosphere for 90 min at 378C and in the dark. After two washes with PBS and with water, respectively, the preparations were mounted with 70% glycerol, 10% PBS and 1 mg/mL p-phenylenediamine (Sigma-Aldrich). The coverslips were viewed with a Zeiss Axioskop (Germany) microscope equipped with epi¯uorescent optics. Pictures were taken with an oil-immersion objective (636) on Ektachrome 400 Kodak ®lm.
DOHH 2 cells, treated with rapamycin, 10 ng/mL at time 0, on day 1 were untreated or treated with taxol at 300, 30 or 3 nM for a further 24 h and then collected, washed twice in PBS for 10 min at 1500 r.p.m. and stained with eosinehematoxylin. The mitotic index was determined by scoring at least 1500 cells on each sample. mTOR activity mTOR was immunopuri®ed as described in with minor modi®cations. Brie¯y, K422 cells, treated with taxol, were washed in cold PBS and lysed at 48C in a solution containing 50 mM Tris/HCL, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 mM b-glycerolphosphate, 0.1 mM Na 3 VO 4 , 0.1 mM PMSF, 5 mg/mL leupeptin, 1 mg/mL aprotinin, 0.2% Triton X-100, 0.3% Nonidet P-40. Lysates, clari®ed by centrifugation at 13 000 r.p.m. for 25 min at 48C, were immunoprecipitated by the rabbit antibodies mTAb1 or mTAb2 (kindly provided by Dr JC Lawrence) . The immune complexes were suspended in 50 mL of kinase buer containing 10 mM 
